Gilead Sciences (GILD) Earnings Date & Reports

Key Takeaways

• Gilead Sciences (GILD) is scheduled to report third quarter 2026 results after the market closes on Thursday, October 29, 2026.
• Wall Street consensus points to earnings of roughly $2.16 per share on revenue near $7.81 billion, implying a year-over-year earnings decline on modestly higher sales.
• Investor attention centers on the HIV franchise, where the Yeztugo (lenacapavir) pre-exposure prophylaxis launch has surpassed a $1 billion annual run rate ahead of schedule.
• Gilead has beaten consensus earnings per share (EPS) estimates in each of its last four quarters, a track record that has supported the stock into this report.
• Management's full-year 2026 guidance and any updates on key regulatory decisions will be closely watched alongside the headline numbers.
• For more detail on Gilead's Major News, Today's Price Move, Price Targets, and Forecast, be sure to explore the additional pages available on Tickeron.
• You can also discover timely trade ideas and market opportunities by exploring Trending AI Robots.

Earnings Context and Why It Matters

Gilead's third quarter report lands at a pivotal moment for the biotechnology company. The launch of Yeztugo, a long-acting HIV prevention medicine, has rapidly become a growth engine, while the company's core HIV treatment portfolio remains the dominant revenue driver. In the second quarter, Gilead delivered stronger-than-expected base business sales and raised its full-year outlook, signaling momentum heading into year-end. At the same time, heavy in-process research and development (IPR&D) charges tied to recent acquisitions weighed on reported results. For investors, the upcoming print is a key test of whether the Yeztugo ramp and HIV franchise durability can offset acquisition costs and sustain the stock's recent outperformance.

Earnings Expectations

For the third quarter of 2026, the Zacks Consensus Estimate calls for earnings of $2.16 per share, a decline of roughly 12.6% from the year-ago period, on revenue of approximately $7.81 billion, up about 0.6% year over year. Other consensus trackers place EPS near $2.17 and revenue near $7.79 billion, reinforcing a broadly flat-to-modestly-lower earnings picture. The earnings comparison reflects a difficult prior-year baseline: Gilead reported $2.47 per share in the third quarter of 2025, a period that benefited from favorable items.

Investors will also weigh non-GAAP (adjusted) figures against reported GAAP results, which can diverge sharply when acquisition-related IPR&D charges are included. In the second quarter of 2026, for example, Gilead recorded a reported loss of $6.75 per share due to $11.2 billion in IPR&D charges from the Arcellx, Tubulis, and Ouro acquisitions, even as base business sales rose 10% year over year. Management has guided full-year 2026 revenue to a range of $30.1 billion to $30.4 billion. Analysts will watch product-level growth in HIV, oncology, and liver disease, along with any commentary on margin trends and the pace of the Yeztugo launch.

AI Screener

Tickeron's AI Screener is an AI-powered stock and exchange-traded fund (ETF) discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help identify trade ideas, trending stocks, breakout candidates, and broader market opportunities more efficiently than manual screening. Explore the AI Screener to refine your own watchlist as earnings season unfolds.

Market Reaction and Investor Sentiment

Sentiment heading into the report has been cautiously optimistic. Gilead's stock has rallied in the weeks since its August earnings release, reflecting enthusiasm around the Yeztugo launch and resilient HIV demand. Analysts have trimmed the consensus EPS estimate only slightly in recent weeks, while the "most accurate estimate" has trended higher, a pattern some models interpret as a signal for a potential upside surprise. Still, the stock has a history of muted or mixed reactions to results even when headline figures beat, as investors focus on guidance and pipeline commentary. Key risk factors include competitive pressure in HIV prevention, pricing dynamics, and the timing of acquisition-related charges, which can obscure underlying operating performance.

Forward Outlook and Key Factors to Monitor

Looking beyond the third quarter, several catalysts will shape Gilead's trajectory. The sustainability of Yeztugo's launch is central: management has guided to roughly $1 billion in first-full-year sales, and investors will watch whether uptake from both new users and switches continues to accelerate. HIV treatment remains the foundation, with Biktarvy and Descovy performance serving as a gauge of franchise health.

Regulatory milestones also matter. Gilead has highlighted anticipated U.S. Food and Drug Administration (FDA) decisions on the BIC/LEN (bictegravir/lenacapavir) combination and on the oncology candidate anito-cel, which could unlock new commercial opportunities in 2027. In oncology, Trodelvy growth and the integration of recently acquired assets such as the Arcellx and Tubulis platforms will be monitored for early signs of pipeline progress.

Finally, investors should track how acquisition-related IPR&D charges and rising research and development spending affect reported profitability, even as base business sales grow. These factors, rather than any single quarterly figure, are likely to determine the stock's longer-term direction.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations